Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
spCART-269 in Relapsed or Refractory Multiple Myeloma
NCT04500431Phase 1Unknown
- Sponsor
- Tongji Hospital
- Start
- Jul 2018
- Primary completion
- Jul 2022
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of spCART-269 in multiple myeloma (MM), sponsored by Tongji Hospital. Primary endpoint: Adverse Events at 12 weeks. Status: unknown.
02
Drugs
spCART-269
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT04500431.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04500431.